AlphaMaven AlphaMaven

TRex Bio Leads 2 Drugmakers Pricing IPOs Totaling $162M

Reported by Law360
Oct 9, 2026· 2 min read
Save Post LinkedIn Email
Key Takeaways
  • • TRex Bio and Retension Pharmaceuticals, two clinical-stage biotechnology firms, priced initial public offerings on Friday, October 9, 2026, raising a combined $162 million, according to Law360.
  • • The offerings were the two biotech IPOs that priced on the same day, with TRex Bio leading the pair in the reported coverage.
  • • The article's reported details are limited to the combined proceeds and the listing date; individual offering sizes, share prices, and underwriters are not disclosed in the available source.
Summary
Two clinical-stage biotechnology companies, TRex Bio and Retension Pharmaceuticals, went public on Friday, October 9, 2026, after raising a combined $162 million in their initial public offerings, according to Law360. The offerings reflect continued access to public equity markets for clinical-stage drug developers, a segment that depends heavily on IPO proceeds to fund trials ahead of commercialization.

The Law360 report frames TRex Bio as the leading company of the two pricings. The source does not break out the amount raised by each firm, nor does it provide offering prices, share counts, exchange listings, or underwriter details. Investors seeking deal-level terms will need to consult the companies' registration statements or a fuller prospectus summary.

For institutional allocators tracking the biotech IPO pipeline, the pairing of two offerings on a single day suggests receptive conditions for early-stage drug developers. Further detail on post-listing trading and the use of proceeds was not available in the source material.

Go deeper than the headline

Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.

Start your free 7-day trial

Sources

1 outlet

AlphaMaven summarised this story from the reporting below. Each link opens the original article.

Law360 TRex Bio Leads 2 Drugmakers Pricing IPOs Totaling $162M